Fact-checked by Grok 2 weeks ago

Vim

'''Vim''' may refer to: == Computing == == Brands and companies == == Science and medicine == == Other uses ==

Computing

Vim (text editor)

Vim is a free and open-source, highly configurable, modal that functions as an improved clone of the original editor, which was developed by in 1976 at the , as a visual interface to the ex line editor. Designed for efficient text manipulation, Vim emphasizes keyboard-driven commands over mouse interactions, making it particularly suited for programming, system administration, and quick edits in terminal environments. Its modal structure—dividing operations into for navigation and commands, insert mode for typing, and visual mode for selections—allows users to perform complex edits rapidly without leaving the keyboard. Bram Moolenaar created Vim in 1991 as "Vi IMproved" for the Amiga operating system, porting it to Unix-like systems the following year to address limitations in existing vi implementations. Development milestones include version 3.0 in 1994, which introduced support for multiple windows; version 5.0 in 1998, adding and folding; version 7.0 in 2006, adding tabbed interfaces and spell-checking; version 8.0 in 2016, enabling asynchronous plugin execution; version 9.0 in 2022, introducing Vim9 script for improved scripting performance; and version 9.1 in 2024, with additional enhancements and bug fixes. These updates have expanded Vim's capabilities while preserving its lightweight footprint and compatibility. Vim's core features include an extensive array of shortcuts for actions like , replacing, and macro recording, alongside a robust that extends functionality through Vimscript or , with thousands of community-contributed extensions available. It supports cross-platform use on systems, Windows, and macOS, and is distributed under the Vim License, a GPL-compatible that encourages donations to as "charityware." Vim holds significant cultural impact in computing, notably as a protagonist in the "editor wars" against Emacs, a debate over modal versus extensible editing paradigms that has shaped hacker culture since the 1980s. Its widespread adoption stems from its ubiquity—pre-installed as the default "vi" on most Unix-like systems—and utility in resource-constrained environments like servers. In the 2024 Stack Overflow Developer Survey, 16.6% of respondents reported using Vim, underscoring its enduring popularity among developers. Following Moolenaar's death on August 3, 2023, from a medical condition, the project continues under community maintainers, including key contributors like Christian Brabandt.

Brands and companies

Vim (cleaning product)

Vim is a longstanding of products, specializing in scouring powders and cream cleaners formulated to tackle stubborn stains and grime on hard surfaces such as sinks, stoves, tiles, and countertops. Originally developed as an cleaner incorporating for emulsification, it represented an early in targeted surface , distinguishing itself from general laundry soaps of the era. The product's name derives from "vigor," emphasizing its robust cleaning power. Launched in 1904 by —founded by William Hesketh Lever—in the , Vim was among the earliest commercially produced scouring powders, marketed as "the latest invention... for Cleaning and Polishing" at a price of 3d per canister. The original formulation relied on silica as the primary , sourced from quarries, combined with soap powder to lift dirt without excessive scratching. Under (formed by the 1929 merger of and ), the brand expanded internationally, becoming a household essential in , , and beyond. In the and early , regional rights shifted through sales, including to Guaber in 2004; by 2015, acquired Vim in key European markets via its purchase of the Spotless Group for €940 million, integrating it into its laundry and home care portfolio. Formulas evolved over decades, with modern iterations incorporating and shifting away from phosphates by the 2010s to align with environmental regulations and reduce risks. Modern formulations are often phosphate-free to meet environmental standards. The brand offers variants in powder and cream forms, with historical powders featuring silica abrasives, soap, and alkaline agents like for enhanced degreasing. The powder version, once dominant, has been discontinued in several markets since around 2020 amid a shift toward gentler liquid alternatives, though it persists in select regions like parts of under names such as Vim Clorex, boasting 93% natural-origin ingredients. Cream cleaners, easier to apply and less abrasive, remain widely available in lemon or neutral scents, using micro-particles for while preserving surface finishes. As of 2025, Vim scouring and cream products maintain presence in several countries worldwide, primarily through in and in select markets such as and , but has largely exited North American markets due to competition from non-abrasive options. Global sales reflect a decline, with the broader segment shrinking as consumers favor eco-conscious liquids; for instance, 's division reported steady but maturing growth in such legacy brands. Culturally, Vim became an icon of mid-20th-century , often depicted in campaigns as the unbeatable fighter against household dirt, symbolizing post-war domestic efficiency in the UK and nations.

VIM Airlines

VIM-Avia, legally known as VIM Airlines, was a Moscow-based charter airline founded in October 2002 by Viktor Ivanovich Merkulov, whose initials inspired the company's name. It began flight operations in December 2002, initially using Soviet-era aircraft such as the Yak-42 before transitioning to Western models, and specialized in leisure and services to popular tourist destinations. Headquartered near , the airline focused on seasonal and ad-hoc flights rather than extensive scheduled networks, capitalizing on Russia's growing outbound market in the . The airline's operations primarily served routes to , and , alongside domestic flights within to over 50 cities. At its peak in the mid-2010s, VIM-Avia operated a fleet of approximately 20 aircraft, including 757-200s, 767-300s, 777-200s, and A319s, enabling medium- and long-haul charter services. The carrier experienced rapid growth after 2010, driven by increased demand for affordable vacation travel, and reported carrying over 2 million passengers in 2016 alone, marking its highest annual figure. Financial difficulties emerged in the mid-2010s due to accumulated debts from fuel, leasing, and operational costs, leading to the of flights on September 23, 2017. With debts exceeding 10 billion rubles (approximately $174 million), the sought support but ultimately ceased all operations by October 16, 2017, after its was revoked. The Arbitration Court of declared VIM-Avia on September 26, 2018, initiating proceedings that concluded the following year. concluded around 2019, with lingering legal cases as of 2025. The collapse stranded around 43,000 passengers abroad, primarily in , , and , prompting emergency repatriation efforts by the and highlighting regulatory gaps in the country's sector. Assets, including much of the fleet, were subsequently sold or acquired by other carriers such as and to mitigate losses. As of 2025, no revival efforts have materialized, and the case remains a prominent example of insolvency risks in Russia's post-Soviet industry, amid broader challenges like and fuel price volatility.

Science and medicine

VIM (gene)

The VIM gene, officially approved by the , is the human gene that encodes , a type III protein crucial for maintaining cytoskeletal integrity in mesenchymal cells. Located on the short arm of chromosome 10 at position 10p13, the gene spans approximately 9,353 base pairs and consists of 10 exons in its canonical transcript. The encoded vimentin protein comprises 466 with a molecular weight of about 53.7 kDa, forming filamentous structures that provide structural support to the cell. Vimentin functions primarily in mechanical reinforcement of the , facilitating , intracellular signaling, and proper positioning of organelles such as the and mitochondria. It is prominently expressed in fibroblasts, endothelial cells, and other mesenchymal-derived cell types, with particularly high levels observed in tissues like the and adipose. During epithelial-mesenchymal transition (), a process critical for and , vimentin expression increases, enabling cells to acquire migratory and invasive properties while downregulating epithelial markers. Clinically, mutations in VIM are associated with congenital cataracts, such as the dominant-negative E151K , which disrupts filament assembly and leads to lens opacification in childhood. Overexpression of vimentin serves as a for in various cancers, including and , where it promotes tumor cell invasion and correlates with poor prognosis. The was first cloned in the mid-1980s using cDNA from lens mRNA, confirming its single-copy status in humans. Key studies in the elucidated its roles in , where vimentin knockout impairs fibroblast proliferation and tissue repair, and in neurodegeneration, such as , where it modulates neuronal stress responses and glial activation. As of November 2025, ongoing clinical trials are exploring vimentin as a target in , including T-cell therapies against cell surface vimentin on circulating tumor cells, such as phase 1 trial NCT05621668 for sarcomas.

VIAAT/VGAT (transport protein)

The vesicular inhibitory amino acid transporter (VIAAT, also known as VGAT), encoded by the SLC32A1 , is a that facilitates the uptake of the inhibitory neurotransmitters gamma-aminobutyric acid () and into synaptic vesicles, enabling their storage and subsequent release at inhibitory synapses in the (CNS). This transporter belongs to the 32 and operates as an , utilizing the proton across the vesicular membrane—generated by vacuolar-type H+-ATPase—to drive neurotransmitter accumulation against concentration gradients. VIAAT/VGAT is essential for inhibitory , as it ensures the quantal release of GABA and glycine, thereby maintaining the balance between excitation and inhibition in neural circuits. VIAAT/VGAT was first identified and cloned in the late 1990s through homology to the unc-47 gene, with seminal work demonstrating its role in vesicular uptake in 1997. Subsequent studies in the , including models, clarified its critical function in CNS development and disorders; for instance, Viaat-null mice exhibit lethal phenotypes due to disrupted inhibitory signaling, highlighting its necessity for survival and normal behavior. Research in the further linked VIAAT/VGAT dysfunction to and anxiety disorders, with reduced expression observed in animal models of and genetic variants associated with with febrile seizures plus (GEFS+). As of 2025, VIAAT/VGAT has emerged as a target in approaches for neurological conditions, such as using recombinant adeno-associated viruses (rAAVs) with Slc32a1 promoters to selectively modulate neurons in and neurodevelopmental disorders. Recent 2025 studies also implicate it in disorder synaptic deficits. Structurally, the human VIAAT/VGAT protein consists of 525 amino acids and features 10 transmembrane domains, forming a topology with both N- and C-termini oriented toward the cytoplasm, which supports its role in vesicular membrane integration. It is predominantly expressed in GABAergic and glycinergic neurons throughout the CNS, including interneurons in the cortex, hippocampus, and spinal cord, where it colocalizes with synaptic vesicle markers. Dysregulation of VIAAT/VGAT has been implicated in psychiatric conditions; for example, reduced VGAT expression in prefrontal cortex GABA neurons correlates with excitatory-inhibitory imbalances in schizophrenia, while genetic perturbations contribute to synaptic deficits in autism spectrum disorders. Recent advances as of 2024 have focused on VIAAT/VGAT modulators for , with studies showing that enhancing VGAT-mediated release in spinal and circuits alleviates chronic in models, potentially through allosteric potentiators or optogenetic activation of VGAT-expressing neurons. These findings underscore VIAAT/VGAT's therapeutic potential without conflicting with the gene (VIM), which encodes an unrelated cytoskeletal protein.

Other uses

Vim (vigor)

Vim is a noun denoting robust , , or spirited , often employed in the idiomatic expression "full of vim and vigor" to describe someone possessing abundant liveliness or drive. This term captures an informal sense of dynamic force, distinguishing it from more clinical descriptions of physical or mental stamina. The word originated as a borrowing from Latin vim, the accusative form of vis, signifying force, strength, or power, and entered English around 1843, gaining traction in 19th-century as a vivid descriptor of energetic . It reflects a playful of classical roots into colloquial usage, evoking the vigor of everyday without technical connotations. In usage, "vim" appears across contexts, from literary portrayals of spirited individuals in 19th-century works to motivational speeches and casual , where it conveys pep, zest, or as near-synonyms. Its cultural prominence peaked in early 20th-century for medicines and tonics, such as Nuxated Iron and Phosphorated , which promised to restore "vim and vigor" to the weary through iron supplements and nerve tonics. By 2025, the term persists in books and fitness discourse, emphasizing sustained enthusiasm in and routines. As an informal, non-technical linguistic element, it lacks formal equations or derivations, relying instead on its evocative brevity in English .

Vim (given name)

Vim is an uncommon masculine , primarily serving as a diminutive of Vimal in Indian and South Asian cultures. Vimal, derived from the word meaning "pure" or "stainless," conveys qualities of clarity and integrity. In Western contexts, Vim occasionally appears as a standalone name inspired by the English noun "vim," denoting energy, vigor, or enthusiasm, which traces back to the Latin vis for "force" or "strength." It has been used rarely as a nickname for longer names like or , though such applications are not widespread. Historical records show limited usage in the early , particularly among immigrant communities in . For instance, Vim Kochhar (born 1936 in , ) emigrated to , where he became a prominent businessman and the first Indo-Canadian appointed to the in 2010, serving until 2011. Such examples highlight its presence in genealogy databases like , but overall occurrences remain sparse, with no entries in U.S. top-1000 rankings for any decade. Culturally, Vim is more prevalent in as a casual shortening of Vimal, reflecting traditional naming practices tied to virtues. The feminine variant Vimi gained visibility through actress (1943–1977), who debuted in the 1967 film and appeared in several productions before her early death. No major celebrities bear the name Vim in contemporary Western media. In modern times, Vim sees occasional creative use in naming, but its popularity is negligible in English-speaking countries, with U.S. birth records indicating fewer than five instances annually in recent years, rendering it effectively obsolete. Search interest remains low globally, confined mostly to cultural or historical queries.